Treatment of epilepsy with mesenchymal stem cells: literature review
R. G. Gamirova,
A. A. Shaymardanova,
A. Yu. Barkov,
A. A. Rizvanov,
D. S. Chulpanova,
A. I. Mullagulova,
V. V. Solovyeva https://doi.org/10.17650/2073-8803-2023-18-1-38-45
Abstract
In the past few years, results from experimental and clinical studies have shown that inflammation can be both a consequence and a cause of epilepsy. Distinctive features of mesenchymal stem cells (MSCs) are their immunomodulatory and anti-inflammatory properties, which indicate promise in the field of epilepsy treatment.
The article presents a review on the preclinical and clinical use of MSCs in the treatment of epilepsy, and outlines the mechanism of MSCs therapeutic action of in this disease. The authors focused on the analysis of all available in the literature clinical cases of MSCs use in the treatment of epilepsy, as well as the effectiveness and undesirable effects of therapy. The use of MSCs indeed has a significant effect in reducing the number of seizures and has a positive effect on mental functions, however, at present, this method of therapy is not ready for widespread clinical use due to the short period of observation in clinical trials and increased risks of developing immunological and oncological complications in patients.
Supporting agencies: This work was supported by the Kazan Federal University Strategic Academic Leadership Program («PRIORITY-2030»).
About the Authors
R. G. Gamirova
Kazan (Volga Region) Federal University
Russian Federation
Russian Federation
Rimma Gabdulbarovna Gamirova
18 Kremlyovskaya St., Kazan 420008
A. A. Shaymardanova
Kazan (Volga Region) Federal University
Russian Federation
Russian Federation
18 Kremlyovskaya St., Kazan 420008
A. Yu. Barkov
Serbsky National Medical Research Center for Psychiatry and Narcology, Ministry of Health of Russia
Russian Federation
Russian Federation
23 Kropotkinskiy Pereulok, Moscow 119034
A. A. Rizvanov
Kazan (Volga Region) Federal University
Russian Federation
Russian Federation
18 Kremlyovskaya St., Kazan 420008
D. S. Chulpanova
Kazan (Volga Region) Federal University
Russian Federation
Russian Federation
18 Kremlyovskaya St., Kazan 420008
A. I. Mullagulova
Kazan (Volga Region) Federal University
Russian Federation
Russian Federation
18 Kremlyovskaya St., Kazan 420008
V. V. Solovyeva
Kazan (Volga Region) Federal University
Russian Federation
Russian Federation
18 Kremlyovskaya St., Kazan 420008
References
1. Abdanipour A., Tiraihi T., Mirnajafi-Zadeh J. Improvement of the pilocarpine epilepsy model in rat using bone marrow stromal cell. Neurol Res 2011;33(6):625–32. DOI: 10.1179/1743132810Y.0000000018
2. Agadi S., Shetty A.K. Concise review: prospects of bone marrow mononuclear cells and mesenchymal stem cells for treating status epilepticus and chronic epilepsy. Stem Cells 2015;33(7):2093–103. DOI: 10.1002/stem.2029
3. Berebichez-Fridman R., Montero-Olvera P.R. Sources and clinical applications of mesenchymal stem cells: state-of-the-art review. Sultan Qaboos Univ Med J 2018;18(3):e264–e277. DOI: 10.18295/squmj.2018.18.03.002
4. Corcione A., Benvenuto F., Ferretti E. et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107(1):367–72. DOI: 10.1182/blood-2005-07-2657
5. Cui L., Kerkelä E., Bakreen A. et al. The cerebral embolism evoked by intra-areterial delivery of allogenic bone marrow mesenchymal stem cells in rats is related to cell dose and infusion velocity. Stem Cell Res Ther 2015;6(1):11. DOI: 10.1186/scrt544
6. Cunningham J.J., Ulbright T.M., Pera M.F. et al. Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol 2012;30(9):849–57. DOI: 10.1038/nbt.2329
7. DaCosta J.C., Portuguez M.W., Marinowic D.R. et al. Safety and seizure control in patients with mesial temporal lobe epilepsy treated with regional superselective intra-arterial injection of autologous bone marrow mononuclear cells. J Tissue Eng Regen Med 2018;12(2):e648–e656. DOI: 10.1002/term.2334
8. Dong H., Li G., Shang C. et al. Umbilical cord mesenchymal stem cell (UC-MSCs) transplantations for cerebral palsy. Am J Transl Res 2018;10(3):901–6.
9. Fischer U.M., Harting M.T., Jimenez F. et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 2009;18(5):683–92. DOI: 10.1089/scd.2008.0253
10. Fukumura S., Sasaki M., Kataoka-Sasaki Y. et al. Intravenous infusion of mesenchymal stem cells reduces epileptogenesis in a rat model of status epilepticus. Epilepsy Res 2018;141:56–63. DOI: 10.1016/j.eplepsyres.2018.02.008
11. Hlebokazov F., Dakukina T., Ihnatsenko S. et al. Treatment of refractory epilepsy patients with autologous mesenchymal stem cells reduces seizure frequency: An open label study. Adv Med Sci 2017;62(2):273–9. DOI: 10.1016/j.advms.2016.12.004
12. Hlebokazov F., Dakukina T., Potapnev M. et al. Clinical benefits of single vs repeated courses of mesenchymal stem cell therapy in epilepsy patients. Clin Neurol Neurosurg 2021;207:106736. DOI: 10.1016/j.clineuro.2021.106736
13. Huang P.Y., Shih Y.H., Tseng Y.J. et al. Xenograft of human umbilical mesenchymal stem cells from Wharton’s jelly as a potential therapy for rat pilocarpine-induced epilepsy. Brain Behav Immun 2016;54:45–58. DOI: 10.1016/j.bbi.2015.12.021
14. Huicong K., Zheng X., Furong W. et al. The imbalanced expression of adenosine receptors in an epilepsy model corrected using targeted mesenchymal stem cell transplantation. Mol Neurobiol 2013;48(3):921–30. DOI: 10.1007/s12035-013-8480-0
15. Jiang W., Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif 2020;53(1):e12712. DOI: 10.1111/cpr.12712
16. Le Blanc K., Rasmusson I., Sundberg B. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363(9419):1439–41. DOI: 10.1016/S0140-6736(04)16104-7
17. Li P., Gong Z., Shultz L.D. et al. Mesenchymal stem cells: From regeneration to cancer. Pharmacol Ther 2019;200:42–54. DOI: 10.1016/j.pharmthera.2019.04.005
18. Liu J., Liu Q., Chen X. The immunomodulatory effects of mesenchymal stem cells on regulatory B сells. Front Immunol 2020;14(11): 1843. DOI: 10.3389/fimmu.2020.01843
19. Long Q., Upadhya D., Hattiangady B. et al. Intranasal MSCs-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. Proc Natl Acad Sci USA 2017;114(17):E3536–E3545. DOI: 10.1073/pnas.1703920114
20. Melief S.M., Schrama E., Brugman M.H. et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 2013;31(9):1980–91. DOI: 10.1002/stem.1432
21. Milczarek O., Jarocha D., Starowicz-Filip A. et al. Multiple autologous bone marrow-derived CD271(+) mesenchymal stem cell transplantation overcomes drug-resistant epilepsy in children. Stem Cells Transl Med 2018;7(1):20–33. DOI: 10.1002/sctm.17-0041
22. Perucca P., Scheffer I.E., Kiley M. The management of epilepsy in children and adults. Med J Aust 2018;208(5):226–33. DOI: 10.5694/mja17.00951
23. Pitkänen A., Lukasiuk K., Dudek F.E. et al. Epileptogenesis. Cold Spring Harb Perspect Med 2015;5(10):a022822. DOI: 10.1101/cshperspect.a022822
24. Pittenger M.F., Discher D.E., Péault B.M. et al. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med 2019;4:22. DOI: 10.1038/s41536-019-0083-6
25. Rana A., Musto A.E. The role of inflammation in the development of epilepsy. J Neuroinflamm 2018;15(1):144. DOI: 10.1186/s12974-018-1192-7
26. Rani S., Ryan A.E., Griffin M.D. et al. Mesenchymal stem cellderived extracellular vesicles: toward cell-free therapeutic applications. Mol Ther 2015;23(5):812–23. DOI: 10.1038/mt.2015.44
27. Ren G., Zhang L., Zhao X. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2(2):141–50. DOI: 10.1016/j.stem.2007.11.014
28. Rodríguez-Fuentes D.E., Fernández-Garza L.E., Samia-Meza J.A. et al. Mesenchymal stem cells current clinical applications: a systematic review. Arch Med Res 2021;52(1):93–101. DOI: 10.1016/j.arcmed.2020.08.006
29. Salem N.A., El-Shamarka M., Khadrawy Y. et al. New prospects of mesenchymal stem cells for ameliorating temporal lobe epilepsy. Inflammopharmacology 2018;26(4):963–72. DOI: 10.1007/s10787-018-0456-2
30. Shaimardanova A.A, Chulpanova D.S., Mullagulova A.I. et al. Gene and cell therapy for epilepsy: a mini review. Front Mol Neurosci 2022 11;15:868531. DOI: 10.3389/fnmol.2022.868531
31. Shi C. Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells. Immunology 2012;136(2):133–8. DOI: 10.1111/j.1365-2567.2012.03567.x
32. Shi Y., Su J., Roberts A.I. et al. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 2012;33(3):136–43. DOI: 10.1016/j.it.2011.11.004
33. Shorvon S. The concept of symptomatic epilepsy and the complexities of assigning cause in epilepsy. Epilepsy Behav 2014;32:1–8. DOI: 10.1016/j.yebeh.2013.12.025
34. Sole A., Grossetête S., Heintzé M. et al. Unraveling ewing sarcoma tumorigenesis originating from patient-derived mesenchymal stem cells. Cancer Res 2021;81(19):4994–5006. DOI: 10.1158/0008-5472.CAN-20-3837
35. Szczepanik E., Mierzewska H., Antczak-Marach D. et al. Intrathecal infusion of autologous adipose-derived regenerative cells in autoimmune refractory epilepsy: evaluation of safety and efficacy. Stem Cells Int 2020;2020:7104243. DOI: 10.1155/2020/7104243
36. Tropel P., Platet N., Platel J. C. et al. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 2006;24(12):2868–76. DOI: 10.1634/stemcells.2005-0636
37. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8(9):726–36. DOI: 10.1038/nri2395
38. Venturin G. T., Greggio S., Marinowic D.R. et al. Bone marrow mononuclear cells reduce seizure frequency and improve cognitive outcome in chronic epileptic rats. Life Sci 2011;89(7–8):229–34. DOI: 10.1016/j.lfs.2011.06.006
39. Voulgari-Kokota A., Fairless R., Karamita M. et al. Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function. Exp Neurol 2012;236(1):161–70. DOI: 10.1016/j.expneurol.2012.04.011
40. Wang L., Zhao Y., Pan X. et al. Adipose-derived stem cell transplantation improves learning and memory via releasing neurotrophins in rat model of temporal lobe epilepsy. Brain Res 2021;1750:147121. DOI: 10.1016/j.brainres.2020.147121
41. Yagi H., Soto-Gutierrez A., Parekkadan B. et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant 2010;19(6):667–79. DOI: 10.3727/096368910X508762
Review
For citations:
Gamirova R.G., Shaymardanova A.A., Barkov A.Yu., Rizvanov A.A., Chulpanova D.S., Mullagulova A.I., Solovyeva V.V. Treatment of epilepsy with mesenchymal stem cells: literature review. Russian Journal of Child Neurology. 2023;18(1):38-45. (In Russ.) https://doi.org/10.17650/2073-8803-2023-18-1-38-45
Views:
454
Email this article 